Aptinyx Inc.
Edit

Aptinyx Inc.

http://www.aptinyx.com/
Last activity: 13.12.2024
Active
Categories: BioTechBuildingDevelopmentHealthTechInvestmentLEDMedTechMessangerPlatformProduct
We are a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system, starting with painful diabetic neuropathy, fibromyalgia, PTSD and Parkinson’s cognitive impairment. We have a proven platform for discovering proprietary compounds that works through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our pipeline of novel clinical candidates to treat indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more about our company or rewarding career opportunities, please visit our website at www.aptinyx.com or follow us on Twitter @Aptinyx
Followers
2.79K
Mentions
32
Location: United States, Illinois, Evanston
Employees: 51-200
Total raised: $135M
Founded date: 2015

Investors 13

Show more

Funding Rounds 2

DateSeriesAmountInvestors
18.12.2017Series B$70MBain Capit...
10.05.2016Series A$65M-

Mentions in press and media 32

DateTitleDescription
13.12.2024Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal DiseasesAngitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ...
12.08.2022Bolt throws a wrench in the pipeline, look­ing to con­serve cashA melt­down in the biotech mar­ket is mak­ing most ex­ecs cau­tious, in­clud­ing Bolt Bio­ther­a­peu­tics’ CEO, as the com­pa­ny hits the brakes on one pre­clin­i­cal as­set and paus­es oth­er ear­ly-stage work to ex­tend cash re­serves by ...
12.08.2022House pass­es his­toric drug pric­ing re­forms, lin­ing up decades-in-the-mak­ing win for Biden and De­moc­ratsIn 2019, Aptinyx’s stock cratered after it reported that its lead candidate failed a diabetic nerve pain trial. After some ‘further analysis,’ the biotech re-upped with that same non-opioid pain drug in two more mid-stage studies — another ...
10.11.2021Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights - Form 8-KAptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromy...
16.09.2021Aptinyx : Secures $50 Million Growth Capital Credit Facility from K2 HealthVenturesAptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and se...
10.08.2021Aptinyx : Initiating CEO transition plan—effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive chairperson and be succeeded by president and COO, Andy Kidd (Form 8-K)Initiating CEO transition plan-effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive chairperson and be succeeded by president and COO, Andy Kidd Conference call today at 5:00 p.m. ET EVANSTON, Ill., August 10,...
10.03.2019Clinical trials of Allergan’s antidepressant rapastinel failThe three studies – RAP-MD-01, -02 and -03 – measured change over a three-week period in baseline measurements on the Montgomery-Asberg Depression Rating Scale, or MADRS, at the end of the study as their primary endpoints, according to Clin...
16.01.2019Aptinyx shares crater as lead drug fails in PhII neu­ro­path­ic pain studyAptinyx’s ap­proach to mod­u­lat­ing the NM­DA re­cep­tor to treat dis­or­ders of the cen­tral ner­vous sys­tem has hit a sig­nif­i­cant snag, as its lead ex­per­i­men­tal drug failed a mid-stage study in pa­tients with di­a­bet­ic pe­riph­...
03.12.20185 Startup Trends that Shaped the Midwest in 2018 1. Marketplaces remain one of the strongest tech sectors 2. Health care gets even hotter 3. Logistics keeps on truckin’ 4. Big bets on enterprise s...2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. Just this week, celebrity shoutout marketplace startup Cameo announced that it closed a $12.5 million round of funding led by Lightspeed Vent...
29.11.20185 startup trends that shaped the Midwest in 2018We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! 2018 is quickly drawing to its close, but the Mid...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In